Precision Medicine Conference

At the Inaugural Columbia Precision Medicine Initiative (CPMI) conference: Advances in Precision Medicine: Genetics, we heard about cutting-edge genetics research from international leaders in the field whose research advances the basic science of genetics and impacts the application of genetics to the understanding and treatment of human genetic disease. 

Accomplishing the objectives of CPMI requires advancing basic science, and the application of the resulting knowledge to the identification of genetic causes of human diseases, the understanding of disease mechanisms, and ultimately to the treatment of a wide range of human diseases ranging from cancer to neurological diseases. To this end, CPMI is a truly University-wide effort. The bedrock of the initiative is strong basic and translational biomedical science practiced in the Medical School, the new Zuckerman Mind Brain and Behavior Institute, and the Morningside campus. Success of the Initiative will also require many other academic disciplines at Columbia ranging from humanities, to engineering, to law and business.

With breathtaking advances in DNA sequencing, computer science, and clinical medicine, it is virtually certain that the number of diseases diagnosed and treated on the basis of genome sequence information will increase dramatically during the next decade. In addition, as we learn more about the relationship between genetic mutations, human biology, and disease, the genome sequence will play a central role in the practice of medicine. I believe the technology is here and essential groundwork has been established. Columbia University is ideally positioned to bring the full force of an extraordinarily diverse and talented faculty to bear on the advancement of precision medicine. 

John Hardy, PhD: Personalized Medicine for the Major Neurodegenerative Diseases: Genetic Predictions & Mechanistic Insights 

Jonathan Pritchard, PhD: The Genetic Architecture of Complex Traits: From Polygenic to Omnigenic

David Goldstein, PhD: Precision Neurology 2017

CPMI Conference 2017
CPMI Conference 2017
CPMI Conference 2017

Accomplishing the objectives of CPMI requires advancing basic science, and the application of the resulting knowledge to the identification of genetic causes of human diseases, to the understanding of disease mechanisms, and ultimately to the treatment of a wide range of human diseases—from cancer to neurological diseases. To this end, CPMI is a truly University-wide effort. The bedrock of the initiative is strong basic and translational biomedical science practiced at Columbia University Irving Medical Center, the Zuckerman Institute, and the Morningside campus. Success of the initiative will also require many other academic disciplines at Columbia ranging from humanities, to engineering, to law and business.

With breathtaking advances in DNA sequencing, computer science, and clinical medicine, it is virtually certain that the number of diseases diagnosed and treated on the basis of genome sequence information will increase dramatically during the next decade. In addition, as we learn more about the relationship between genetic mutations, human biology, and disease, the genome sequence will play a central role in the practice of medicine. I believe that Columbia University, as a great liberal arts and scientific institution, is ideally positioned to bring the full force of an extraordinarily diverse and talented faculty to bear on the advancement of precision medicine.

Columbia University is a world leader in medicine, science, and technology, from fundamental discoveries to the clinic. The Columbia Precision Medicine Initiative (CPMI) utilizes the vast intellectual resources of Columbia faculty to drive this revolution in health care.

Advances in Precision Medicine: Cancer Genomics was held on Monday April 9th, 2018, on the Columbia University Medical Campus. We hosted 10 top international speakers, together bringing a broad focus spanning from research insights to clinical applications of cancer genomics.

Arul M. Chinnaiyan, University of Michigan

Luis Diaz, Memorial Sloan Kettering Cancer Center

Arnold Levine, Institute for Advanced Studies

William C. Hahn, Broad Institute; Dana-Farber Cancer Institute

Serena Nik-Zainal, University of Cambridge

Raul Rabadan, Columbia University

Nitzan Rosenfeld, University of Cambridge

Charles Sawyers, Memorial Sloan Kettering Cancer Center

David Tuveson, Cold Spring Harbor Laboratory

Catherine Wu, Broad Institute; Dana-Farber Cancer Institute

CPMI 2nd Annual Conference
CPMI 2nd Annual Conference
CPMI 2nd Annual Conference
CPMI 2nd Annual Conference